Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Background/Aims Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance may enhance dose and treatment s...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Korean Association for the Study of Intestinal Diseases 2021-01-01
Saila:Intestinal Research
Gaiak:
population pharmacokinetics
vedolizumab
colitis, ulcerative
crohn disease
asian
Sarrera elektronikoa:http://www.irjournal.org/upload/pdf/ir-2019-09167.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-2019-09167.pdf

Antzeko izenburuak